Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immunic (IMUX)
NASDAQ:IMUX
IMUX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.92 - $2.11
Previous CloseN/A
Volume261.21K
Average Volume (3M)918.20K
Market Cap
$98.19M
Enterprise Value$108.93M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.30
Next Earnings
Feb 20, 2025EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.24
Shares Outstanding90,079,020
10 Day Avg. Volume636,407
30 Day Avg. Volume918,203
Standard Deviation0.23
R-Squared0.18
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.11
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-981.33
Enterprise Value/Ebitda-1.14
Forecast
1Y Price Target
$7.00Price Target Upside566.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Immunic News
PremiumCompany Announcements
Immunic, Inc. Advances MS Trials Amid Financial Update
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe expert gave the CALLIPER trial a 75-80% probability of success in showing significant benefits based on current data.
Mechanism Of ActionVidoCa is chemically distinct from Aubagio, offering enhanced potency and neuroprotective Nurr1 activity.
Treatment InnovationIncreased confidence in vidofludimus calcium's differentiated approach to treating the full MS spectrum, attacking both relapsing and progressive forms.
Bears Say
Market CompetitionVidofludimus calcium could remain the last oral option standing for full spectrum MS treatment given past tolerability troubles with the BTK drug class.
Recognition Of MechanismVidoCa’s novel mechanism of action is not well-appreciated, as it involves both DHODH inhibition and Nurr1 activation, which may be well-suited to treat multiple aspects of MS pathology.
Regulatory ChallengesBTK inhibitors face challenges due to past failures and tolerability concerns, which cloud the path to regulatory success.
---
Ownership Overview
9.12% Insiders
6.35% Mutual Funds
40.21% Other Institutional Investors
39.83% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IMUX FAQ
What was Immunic’s price range in the past 12 months?
Immunic lowest stock price was $0.92 and its highest was $2.11 in the past 12 months.
What is Immunic’s market cap?
Immunic’s market cap is $98.19M.
When is Immunic’s upcoming earnings report date?
Immunic’s upcoming earnings report date is Feb 20, 2025 which is yesterday.
How were Immunic’s earnings last quarter?
Currently, no data Available
Is Immunic overvalued?
According to Wall Street analysts Immunic’s price is currently Undervalued.
Does Immunic pay dividends?
Immunic does not currently pay dividends.
What is Immunic’s EPS estimate?
Immunic’s EPS estimate is -0.24.
How many shares outstanding does Immunic have?
Immunic has 90,079,020 shares outstanding.
What happened to Immunic’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Immunic?
Currently, no hedge funds are holding shares in IMUX
---
Immunic Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.00 (566.67% Upside)
$7.00 (566.67% Upside)
Blogger Sentiment
Bullish
IMUX Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $99.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.66%
12-Months-Change
Fundamentals
Return on Equity
-216.24%
Trailing 12-Months
Asset Growth
-3.31%
Trailing 12-Months
Company Description
Immunic
Immunic, Inc. engages in developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its products include IMU-838, IMU-935, and IMU-856. The company is headquartered in San Diego, CA.
---
IMUX Company Deck
---
IMUX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented significant positive developments, including strengthened leadership, progress in key clinical trials, and potential market impact of vidofludimus calcium. However, challenges such as increased R&D expenses and net losses were also noted. The sentiment leans slightly positive due to the promising clinical trial results and potential market opportunities.Read More>---
IMUX Stock 12 Month Forecast
Average Price Target
$7.00
▲(566.67% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
BioCryst
―
Cytokinetics
―
RedHill Biopharma
―
Viking Therapeutics
―
Best Analysts Covering IMUX
1 Year
1 Year Success Rate
2/9 ratings generated profit
1 Year Average Return
-21.07%
reiterated a buy rating a year ago
Copying Andreas Argyrides's trades and holding each position for 1 Year would result in 22.22% of your transactions generating a profit, with an average return of -21.07% per trade.
---